Trial Profile

Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapiglutide (Primary)
Indications Obesity
Focus Proof of concept; Therapeutic Use
Acronyms DREAM

Most Recent Events

05 Dec 2024 Planned End Date changed from 15 Aug 2024 to 15 Aug 2025.
15 Aug 2024 According to a Zealand Pharma media release, the company anticipates topline results expected in the first half of 2025.The added cohort will have no impact on the expected timing for initiation of a Phase 2b trial in the first half of 2025.
23 May 2024 Results were presented in a Zealand Pharma Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com